Skip to main content
. 2022 Jun 28;37(4):800–810. doi: 10.3904/kjim.2021.348

Table 3.

Comparison of treatment between two groups in NIAP

Initial empiric antibiotics for NIAP Overall (n = 379) Treatment failure (n = 119) Treatment success (n = 260)
Monotherapy 192 (50.7) 53 (44.5) 139 (53.5)
 B-lactam antibiotics 177 (46.7) 50 (42.0) 127 (48.8)
 Fluoroquinolones 6 (1.6) 0 6 (1.6)
 Glycopeptides 1 (0.3) 0 1 (0.4)
 Aminoglycosides 2 (0.5) 0 2 (0.8)
 Miscellaneous 6 (1.6) 3 (2.5) 3 (1.2)
Dual combination therapy 161 (42.5) 52 (43.7) 109 (41.9)
 B-lactam + Fluoroquinolones 114 (30.1) 29 (24.4) 85 (32.7)
 B-lactam + Glycopeptides 28 (7.4) 13 (10.9) 15 (5.8)
 B-lactam + Aminoglycosides 5 (1.3) 3 (2.5) 2 (0.8)
 B-lactam + Nitroimidazoles 5 (1.3) 3 (2.5) 2 (0.8)
 B-lactam + Macrolides 7 (1.8) 2 (1.7) 5 (1.9)
 Miscellaneous 4 (1.1) 2 (1.7) 2 (0.8)
Triple combination therapy 21 (5.5) 11 (9.2)a 10 (3.8)
 B-lactam + Fluoroquinolones + Glycopeptides 10 (2.6) 6 (5.0) 4 (1.5)
 B-lactam + Fluoroquinolones + Nitroimidazoles 2 (0.5) 1 (0.8) 1 (0.4)
 B-lactam + Aminoglycosides + Glycopeptides 1 (0.3) 1 (0.8) 0
 B-lactam + Aminoglycosides + Nitroimidazoles 1 (0.3) 0 1 (0.4)
 Miscellaneous 7 (1.8) 3 (2.5) 4 (1.5)
Duration of antibiotics, day 12 (7–24) 10 (5–25) 12 (7–22)
Adequacy of initial antibioticsc 57 (55.9) 25 (55.6) 32 (56.1)
Change of antibiotics after pathogen confirm 132 (34.8) 51 (42.9)a 81 (31.2)
 Escalation of antibiotics 75 (56.4) 33 (63.5) 42 (51.9)
 De-escalation of antibiotics 24 (18.0) 6 (11.5) 18 (22.2)
Adjunctive corticosteroid treatment 63 (16.6) 29 (24.4) 34 (13.1)b

Values are presented as number (%) or median (interquartile range).

NIAP, non-ICU-acquired pneumonia.

a

p value was less than 0.05.

b

p value was less than 0.01.

c

Only 102 patients of all NIAP patients (treatment failure 45; treatment success 57) could determine whether initial empiric antibiotics were adequate.